Galectin-3-IN-4, identified by its CAS number 2496515-38-7, is a small molecule inhibitor specifically targeting galectin-3, a protein involved in various biological processes, including cell adhesion, proliferation, and apoptosis. This compound is of interest in biomedical research due to its potential therapeutic applications in cancer, fibrosis, and inflammatory diseases, where galectin-3 plays a significant role in disease progression. The characteristics of Galectin-3-IN-4 include its molecular structure, which typically features specific functional groups that facilitate binding to the galectin-3 protein, thereby inhibiting its activity. The compound's solubility, stability, and bioavailability are also critical factors that influence its efficacy as a therapeutic agent. Additionally, studies may explore its pharmacokinetics and pharmacodynamics to understand its behavior in biological systems. Overall, Galectin-3-IN-4 represents a promising avenue for drug development targeting galectin-3-related pathways in various diseases.

Galectin-3-IN-4

2496515-38-7: Galectin-3-IN-4, identified by its CAS number 2496515-38-7, is a small molecule inhibitor specifically targeting galectin-3, a protein involved in various biological processes, including cell adhesion, proliferation, and apoptosis. This compound is of interest in biomedical research due to its potential therapeutic applications in cancer, fibrosis, and inflammatory diseases, where galectin-3 plays a significant role in disease progression. The characteristics of Galectin-3-IN-4 include its molecular structure, which typically features specific functional groups that facilitate binding to the galectin-3 protein, thereby inhibiting its activity. The compound's solubility, stability, and bioavailability are also critical factors that influence its efficacy as a therapeutic agent. Additionally, studies may explore its pharmacokinetics and pharmacodynamics to understand its behavior in biological systems. Overall, Galectin-3-IN-4 represents a promising avenue for drug development targeting galectin-3-related pathways in various diseases.

Galectin-3-IN-4 (compound 5), a carboxamide analog, effectively and selectively inhibits both human and mouse galectin-3. This compound demonstrates notable potency with IC50 values of 21 nM for hGal-3 and 167 nM for mGal-3. It is also orally bioavailable. For other galectins, Galectin-3-IN-4 shows IC50 values of 1580 nM for hGal-1 and 2750 nM for hGal-9, respectively [1].

CAS 2496515-38-7

Galectin-3-IN-4

Galectin-3-IN-4

Ref: TM-T86487